About Us

Mr. Huen serves as Chairman of the Board and Chief Executive Officer of Niki BioSolutions. He founded Aptorum Group Limited and served as its Chief Executive Officer and Executive Director, including from October 2017 to May 2022 and again from November 2023. He has more than 18 years of experience in global asset management, including as an equity research analyst covering U.S. healthcare at Janus Henderson Group plc, and served as a financial advisor in the 2007 sale of Seng Heng Bank to Industrial and Commercial Bank of China. He is a trustee board member of the Dr. Stanley Ho Medical Development Foundation. Mr. Huen holds an A.B. in Economics from Princeton University and an M.A. in Comparative and Public History from The Chinese University of Hong Kong, and is a Chartered Financial Analyst.

Dr. Mireskandari serves as President and Chief Operating Officer of Niki BioSolutions and as Chief Executive Officer of DiamiR Biosciences, and is a non-voting observer to the Board. He has more than 15 years of experience in the development and commercialization of molecular diagnostics. He previously served as Chief Development Officer at Interpace Biosciences (2013–2022) and as President and Chief Executive Officer of JS Genetics (2009–2013). Earlier in his career, he managed life sciences portfolios at Nomura Securities, BNP Paribas, and Raeburn Advisors, and conducted research at the National Cancer Institute. Dr. Mireskandari holds a PhD in Genetics from The George Washington University and an MBA from the University of Michigan Ross School of Business.

Thomas Freeburg serves as Chief Financial Officer of Niki BioSolutions, Inc. (Nasdaq: NIKI). He brings more than 25 years of financial leadership, SEC reporting, and accounting experience across publicly traded companies in the life sciences, consumer, and publishing sectors.

Prior to joining Niki BioSolutions, Mr. Freeburg was Managing Member of Cambridge Accounting Group, LLC, where he provided financial and accounting advisory services to growth-stage companies. He previously spent more than five years at Interpace Biosciences, Inc. (Nasdaq: IDXG), a molecular diagnostics company, serving as Chief Financial Officer, Secretary and Treasurer from 2021 to 2023 and as Chief Accounting Officer from 2017 to 2021. Earlier in his career, he was Director of SEC Reporting and Accounting Policies at Coach, Inc. (now Tapestry, Inc., NYSE: TPR) and Director of External Reporting at Scholastic Corporation (Nasdaq: SCHL). He began his career in public accounting as an auditor with BDO.

Dr. Kumar has over 30 years of experience in diagnostic test development with expertise in Molecular and Cellular Biology, DNA tumor virology, and product development, validation, and launch of diagnostic tests. He has secured research grants from NIH and the American Cancer Society (1988–1997) and has authored 42 peer-reviewed publications. He is also DiamiR’s New York State CQ-certified lab director in Oncology; Molecular and cellular tumor markers. Dr. Kumar is a co-author on 44 peer-reviewed publications; he has a Ph.D. in Organic Chemistry from the University of Lucknow, Lucknow, India, and completed his post-doctorate education at USC and Yale University.

Henry “Harv” Rinder, MD, is a board-certified Professor of Laboratory Medicine and of Medicine (Hematology) and serves as Vice Chair for Clinical Affairs, Laboratory Medicine, Yale University School of Medicine, and Associate Director, Yale Pathology Residency Program. He is also Director, Clinical Hematology Laboratory at YNHH. He is the past President of the American Society of Clinical Pathologists (2021–2022) and serves as a technical advisor to DiamiR laboratory operations. He is cited as a co-author in over 190 peer-reviewed publications. Dr. Rinder received his MD from the University of Vermont and his Fellowship from Yale University School of Medicine.

Robert A. Rissman, PhD, is Professor of Physiology and Neuroscience and holder of the W.M. Keck Endowed Chair in Medicine at the Keck School of Medicine of USC, where he is founding Director of the Neuroscience Translational Research Division at the Alzheimer’s Therapeutic Research Institute (ATRI). His research focuses on discovering and validating blood-based biomarkers for Alzheimer’s disease, including plasma and neuronal-exosome markers that detect amyloid pathology and predict progression to dementia. Author of more than 200 peer-reviewed publications, he received the Journal of Alzheimer’s Disease’s 2024 Alzheimer Award and earned his PhD in neuroscience from Drexel University College of Medicine.

Sydney Finkelstein, MD, is DiamiR’s CLIA lab director and is board-certified in Anatomical and Neuropathology. He is also a CAP/CLIA inspector with extensive experience in LDT and diagnostic test development. Dr. Finkelstein is also an Adjunct Professor of Pathology at Drexel University, where he lectures in molecular pathology and works with the residents in training on clinical and research applications and has authored over 220 peer-reviewed papers. Dr. Finkelstein received his MD degree from McGill University School of Medicine and completed his residency in anatomical and neuropathology at the University of Toronto Teaching Hospital and completed his fellowship in experimental Pathology at Hahnemann University School of Medicine.